Meeting
2016 ASCO Annual Meeting
Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
Authors
Bert H. O'Neil
Indiana University, Simon Cancer Center, Indianapolis, IN
Bert H. O'Neil , Joleen Marie Hubbard , Alexander Starodub , Derek J. Jonker , William Jeffery Edenfield , Bassel F. El-Rayes , Thorvardur Ragnar Halfdanarson , Ramesh K. Ramanathan , Henry C. Pitot , Carolyn D. Britten , Bamidele Adesunloye , Axel Grothey , Laura Borodyansky , Chiang Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT02024607
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3564)
DOI
10.1200/JCO.2016.34.15_suppl.3564
Abstract #
3564
Poster Bd #
261
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).
First Author: Johanna C. Bendell
Poster
2015 ASCO Annual Meeting
A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC).
First Author: Joleen Marie Hubbard
Poster
2018 ASCO Annual Meeting
Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
First Author: Vera Gorbunova
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers.
First Author: Scott Kopetz